Manufacturer of Controlled Substances; Notice of Registration; Siegfried (USA), 30027-30028 [2012-12274]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices
30027
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 20, 2012.
Schedule
manufacturer of Tapentadol (9780), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 20, 2012.
Dated: May 9, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Austin Pharma, LLC.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 11, 2012,
Austin Pharma, LLC., 811 Paloma Drive,
Suite C, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Schedule
ebenthall on DSK5SPTVN1PROD with NOTICES
I
I
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
VerDate Mar<15>2010
19:32 May 18, 2012
Jkt 226001
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 15, 2012,
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
BILLING CODE 4410–09–P
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
[FR Doc. 2012–12280 Filed 5–18–12; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Application;
American Radiolabeled Chemicals, Inc.
[FR Doc. 2012–12284 Filed 5–18–12; 8:45 am]
Drug
Dated: May 9, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Dimethyltryptamine (7435) ...........
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Heroin (9200) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Metazocine (9240) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Phenazocine (9715) .....................
Carfentanil (9743) .........................
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Fentanyl (9801) ............................
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 20, 2012.
Dated: May 9, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12251 Filed 5–18–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Siegfried (USA)
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2323, Siegfried
(USA), 33 Industrial Park Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Dihydromorphine (9145) ...............
Hydromorphinol (9301) .................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Oxymorphone (9652) ...................
E:\FR\FM\21MYN1.SGM
21MYN1
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
30028
Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices
The company plans to manufacture the
listed controlled substances in bulk for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siegfried (USA), to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Siegfried (USA), to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR
§ 1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62449,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
ebenthall on DSK5SPTVN1PROD with NOTICES
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
II
II
II
The company plans to manufacture
the listed controlled substance
Noroxymorphone (9668), in bulk for
sale to its customers. It plans to
manufacture the other two listed
controlled substances in bulk for dosage
form development, clinical trials, and
use in stability qualification studies.
No comments or objections have been
received. DEA has considered the
Jkt 226001
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Cedarburg
Pharmaceuticals, Inc., 870 Badger
Circle, Grafton, Wisconsin 53024, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
4-Anilino-N-phenethyl-4-piperidine
(8333).
Fentanyl (9801) ............................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12271 Filed 5–18–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.,
Pharmaceuticals Materials
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
18:18 May 18, 2012
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12275 Filed 5–18–12; 8:45 am]
[FR Doc. 2012–12274 Filed 5–18–12; 8:45 am]
VerDate Mar<15>2010
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Johnson
Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Schedule
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers. The Thebaine
(9333) will also be used to manufacture
other controlled substances in bulk
which will also be for sale in bulk to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc., Pharmaceuticals
Materials to manufacture the listed basic
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 77, Number 98 (Monday, May 21, 2012)]
[Notices]
[Pages 30027-30028]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12274]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Siegfried (USA)
By Notice dated January 6, 2012, and published in the Federal
Register on January 17, 2012, 77 FR 2323, Siegfried (USA), 33
Industrial Park Road, Pennsville, New Jersey 08070, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Dihydromorphine (9145)..................... I
Hydromorphinol (9301)...................... I
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Oripavine (9330)........................... II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
[[Page 30028]]
The company plans to manufacture the listed controlled substances in
bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Siegfried (USA), to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Siegfried (USA), to ensure that the company's registration
is consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823(a), and in accordance with 21 CFR Sec. 1301.33, the
above named company is granted registration as a bulk manufacturer of
the basic classes of controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12274 Filed 5-18-12; 8:45 am]
BILLING CODE 4410-09-P
